BioChem Pharma wins patent dispute over 3TC.
In December 2000, the US Board of Patent Appeals and Interferences, a branch of the US Patent and Trademark Office (USPTO), upheld BioChem Pharma's claim to hold the patent on 3TC.
D006801:Humans; D019259:Lamivudine; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D018894:Reverse Transcriptase Inhibitors
D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine